Eli Lilly has partnered with Amazon Pharmacy to help fill online orders of its obesity drug Zepbound—as well as migraine and diabetes medicines—placed through the pharma’s online portal LillyDirect.
Ionis Pharmaceuticals said on Wednesday its experimental drug to treat a type of fatty liver disease met the main goal of reducing inflammation of the critical organ in a mid-stage trial.
The company, whose products includes Cetaphil, a product for damaged and sensitive skin, as well as fillers and skin creams, early on Wednesday announced a price range of 49 to 53 Swiss francs for its flotation – likely to be one of the biggest in Europe this year.
Merck & Co said it plans to conduct clinical trials testing its human papillomavirus (HPV) vaccine Gardasil 9 to evaluate the efficacy and safety of a single-dose regimen compared to the approved three-dose regimen.
An unmet need in the contraceptive field is availability and access for patients. Almost half of the 6.1 million pregnancies in the United States annually are unintended, so the approval of Opill to be sold over the counter without a prescription allows increased accessibility, promoting timely use and reducing barriers to family planning, according to GlobalData.
The injectable drug imetelstat was being studied in patients with lower risk myelodysplastic syndromes (MDS), a type of blood cancer, which requires frequent blood transfusions for managing anemia.
Challenges transitioning new clinicians from academic training to professional practice tops ECRI’s 2024 list of top 10 patient safety concerns for 2024 released by one of the nation’s largest patient safety organizations. ECRI researchers compiled the report by drawing on evidence-based research, data, and expert insights.
Yesterday the agency published a revised draft guidance document, aimed at helping sponsors and pharmaceutical companies to develop therapies for Alzheimer’s disease, particularly in its early stages before the onset of overt dementia.
In a neurology update for investors, Roche touted data from a small Ib/IIa trial for trontinemab, an investigational therapy for Alzheimer’s disease which demonstrated “rapid and robust” amyloid plaque reduction.
Acadia Pharmaceuticals is terminating development of its antipsychotic drug pimavanserin, which did not demonstrate a statistically significant improvement over placebo in the late-stage study’s primary endpoint.
